-

The Cystic Fibrosis Foundation Affirms Support of the Introduction of the PASTEUR Act

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones. The organization issued the following statement:

“New solutions are needed now to bring novel antibiotics into the hands of patients. The Cystic Fibrosis Foundation applauds Senators Bennet and Young in reintroducing the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. If passed, the PASTEUR Act has the potential to spur vital investment into new antibiotics by addressing the economic disincentives that have long been associated with antibiotic development.

“Routine use of antibiotics in cystic fibrosis care is medically necessary but unfortunately, too many people with CF find themselves battling difficult-to treat infections where existing antibiotics are not effective. However, antibiotic resistance is not solely a CF problem—it’s a human problem that we can no longer ignore.

“People with CF need more antibiotic options as do all Americans. The Foundation is making significant investments into the research and development of new approaches to address infections, but more is needed. Congress must take swift action to pass the PASTEUR Act, invigorating a new era of antibiotic research and development that could bring novel treatments into the hands of patients who need them the most.”

For more information about the Foundation’s work in fighting antimicrobial resistance, visit cff.org.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org.

Contacts

Ashley Mahoney
Email: amahoney@cff.org
Phone: 240-200-3754

Cystic Fibrosis Foundation


Release Versions

Contacts

Ashley Mahoney
Email: amahoney@cff.org
Phone: 240-200-3754

More News From Cystic Fibrosis Foundation

Cystic Fibrosis Foundation Announces Adela Skenderasi as Next Chief Investment Officer

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that Adela Skenderasi, CFA, will join the organization as its next Chief Investment Officer (CIO) on October 13, 2025. “Adela has proven experience as an outstanding leader, managing investments for nonprofit, purpose-driven organizations like the Cystic Fibrosis Foundation. We are confident her strategic insights will help successfully drive the Foundation’s investment strategy,” said Michael Boyle, MD, president a...

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis (CF). Prime Medicine uses a gene editing technology called prime editing — a technology that enables a wide range of modifications to the DNA with a high degree of precision. The company — founded by Drs. David Liu and Andrew Anzalone, who pioneered the development of...

CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy

BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia Therapeutics. The funding is intended to be used to develop a gene editing therapy that could be delivered into the lung cells of people with cystic fibrosis. ReCode is focused on developing a version of its lipid nanoparticles that is optimized for delivery to lung stem cells, the ideal target for a permanent gene...
Back to Newsroom